Advances and Challenges in Dynamic Bioimage Analysis
Erik Meijering, School of Computer Science and Engineering, University of New South Wales, Australia
How to Cross the Border from R to D? - The Example of Conception of New Medical Devices
Lionel Pazart, Tech4Health/ F-CRIN, Inserm, CHU Besançon, France
Enchanted Objects - Design, Human Desire and the Internet of Things
David Rose, Independent Researcher, United States
Advances and Challenges in Dynamic Bioimage Analysis
Erik Meijering
School of Computer Science and Engineering, University of New South Wales
Australia
https://imagescience.org/meijering/
![]()
Brief Bio
Erik Meijering is a Professor of Biomedical Image Computing in the School of Computer Science and Engineering at the University of New South Wales (UNSW), Sydney, Australia. He received the MSc degree in Electrical Engineering from Delft University of Technology (1996) and the PhD degree in Medical Image Analysis from Utrecht University (2000), both in the Netherlands. Before joining UNSW (2019), he was a Postdoctoral Fellow at the Swiss Federal Institute of Technology in Lausanne, Switzerland (2000-2002), an Assistant Professor at Erasmus University Medical Center in Rotterdam, the Netherlands (2002-2008), and an Associate Professor at the same institute (2008-2019). He is a Fellow of the Institute of Electrical and Electronics Engineers (IEEE) and was/is a member of the IEEE Signal Processing Society Technical Committee on Bio Imaging and Signal Processing (BISP, 2005-2010, 2016-2020, Chair 2018-2019), the IEEE Engineering in Medicine and Biology Society Technical Committee on Biomedical Imaging and Image Processing (BIIP, since 2007), and the cross-Society IEEE Life Sciences Technical Community (LSTC, 2018-2020). Over the years he was/is an Associate Editor for the IEEE Transactions on Medical Imaging (2004-2024), the International Journal on Biomedical Imaging (2006-2009), and the IEEE Transactions on Image Processing (2008-2011). He has also co-edited various journal special issues, including for the IEEE Transactions on Image Processing (2005) and the IEEE Signal Processing Magazine (2015, 2022), has co-organized three international benchmarking competitions (Particle Tracking Challenge 2012, Cell Tracking Challenge since 2013, BigNeuron Project since 2015), and has co-organized various conferences in the field, most notably the IEEE International Symposium on Biomedical Imaging (ISBI, especially 2006, 2010, 2018 as Technical Program Chair) and the International Conference on Medical Image Computing and Computer-Assisted Intervention (MICCAI 2020 as Workshops Chair), and served/serves on a great variety of other conference, advisory, and review boards.
Abstract
The capacity of any living organism to survive depends on a multitude of cellular and molecular dynamic processes, including metabolism, immune response, mitosis, and embryogenesis. To ultimately combat many diseases it is of fundamental importance to acquire full understanding of these biological processes. In the past two decades, scientific investigations to this end have been catalyzed by Nobel-prize winning advances in bioimaging, allowing biologists to visualize cells and intracellular components with very high spatiotemporal resolution and sensitivity. As a result, typical live-cell imaging experiments using time-lapse microscopy nowadays produce gigabytes of image data, containing vast amounts of objects to be tracked and analyzed. Many computerized image analysis methods have already been developed to perform this task quantitatively, objectively, and efficiently. We will discuss historical developments and recent advances in automated bioimage analysis for cell and particle tracking applications. In addition, we will discuss the design and results of international challenges to gain more insight in the absolute and relative performance of computational methods and software tools for these applications, leading to important conclusions for practitioners as well as method developers.
How to Cross the Border from R to D? - The Example of Conception of New Medical Devices
Lionel Pazart
Tech4Health/ F-CRIN, Inserm, CHU Besançon
France
http://www.chu-besancon.fr/
Brief Bio
Lionel Pazart is a French M.D. and has completed a Ph.D from Lille 2 University and postdoctoral studies from Brussels University School of Medicine (MPH). He is currently the director of Inserm CIT808 at Besancon University Hospital, a clinical research center dedicated to develop innovative technologies. He has published more than 75 papers in peer-review international journals, more than 150 communications and holds 14 patents.
Abstract
The border between Research and Development for a new medical device is often unclear since the process of its development remains non linear and requires feedback from trials in clinical situation to new conception of the product. More importantly, the classification of the different steps of a project impacts on 1/ the identification of right partners for the project, 2/ state aid intensities, generally lower for activities linked to development than for research related activities 3/ impact factor of publication related to the translational phase of the project. Sometimes researchers under-estimate these translational studies because it is thought that, although essential to set-up new investigation tools, they do not lead to an increase of fundamental knowledge. However, and especially in the field of medical devices, users have to face specific difficulties due to the variability of the biological systems under study. Results obtained in translational research often depend on this variability and new questions or scientific obstacles arise from the confrontation to the real world. In order to address these new challenges, reverse translational research is required. Fundamental research is then fuelled from the results of translational research. In this conference, we would like to present a useful model of medical device development through several examples of translational research in order to illustrate the adequacy of research to bridging fundamental research results to the closest to the patients.
Enchanted Objects - Design, Human Desire and the Internet of Things
David Rose
Independent Researcher
United States
![]()
Brief Bio
Product designer, teacher, and serial entrepreneur. Currently CEO at Vitality, a wireless health company that makes the award-winning GlowCap, the first Internet-connected medication packaging. David was co-founder and CEO of Ambient Devices where he created glanceable technology: embedding Internet information in everyday objects like light bulbs and umbrellas to make the physical objects an interface to digital information. David founded Viant’s Innovation Center, an advanced technology group for Fortune 500s including Sony, GM, Schwab, Sprint and Kinkos. He helped build Viant to over 900 people, $140M and a successful IPO.In 1997 Rose patented online photo-sharing with Neil Mayle and founded Opholio (acquired by FlashPoint Technology).Before the Internet he founded and was President of Interactive Factory (acquired by RDW Group) which still creates interactive museum exhibits, educational software and smart toys, including the award-winning LEGO Mindstorms Robotic Invention System.David co-teaches a popular course in tangible user interfaces at the MIT Media Lab with Hiroshi Ishii. He is a frequent speaker to corporations and design and technology conferences. He received his BA in Physics from St. Olaf College, studied Interactive Cinema at the MIT Media Lab, and earned a Masters at Harvard.
Abstract
Some believe the future will look like more of the same—more smartphones, tablets, screens embedded in every conceivable surface. David Rose has a different vision: technology that atomizes, combining itself with the objects that make up the very fabric of daily living. Such technology will be woven into the background of our environment, enhancing human relationships and channeling desires for omniscience, long life, and creative expression. The enchanted objects of fairy tales and science fiction will enter real life.